{"id":"bnt162b2-ba-4-5-bivalent","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain medications (e.g., ibuprofen, naproxen)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants (e.g., heparin, enoxaparin)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents (e.g., clopidogrel, ticagrelor)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased effectiveness of vaccine"},{"drug":"Interferon-alpha","action":"Avoid","effect":"Decreased effectiveness of vaccine"},{"drug":"Immunosuppressants (e.g., corticosteroids, cyclosporine)","action":"Monitor","effect":"Decreased effectiveness of vaccine"},{"drug":"Chloroquine","action":"Avoid","effect":"Decreased effectiveness of vaccine"},{"drug":"HIV protease inhibitors","action":"Monitor","effect":"Decreased effectiveness of vaccine"}],"commonSideEffects":[],"contraindications":["Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.","Events of anaphylaxis have been reported.","Subsequent dose(s) of the vaccine should not be given to those who have experienced anaphylaxis to the earlier dose of COMIRNATY.","Myocarditis and pericarditis","Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection.","Thrombocytopenia and coagulation disorders","Immunocompromised individuals"],"specialPopulations":{"Pregnancy":"There is limited experience with use of COMIRNATY in pregnant women. Administration of COMIRNATY in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus. No data are available yet regarding the use of COMIRNATY (Bivalent) during pregnancy.","Geriatric use":"text","Paediatric use":"The safety and efficacy of COMIRNATY (Bivalent) in children aged less than 6 months has not yet been established. COMIRNATY (Bivalent) should be administered intramuscularly (see section 6.6). The preferred site for injection is the deltoid muscle of the upper arm.","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b2-ba-4-5-bivalent","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:49.514974+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:56.114107+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:49.536446+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b2-ba-4-5-bivalent","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:56.996240+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5791340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:58.106172+00:00"}},"allNames":"bnt162b2 ba.4/5 bivalent","offLabel":[],"timeline":[],"aiSummary":"BNT162b2 BA.4/5 bivalent is a marketed COVID-19 vaccine developed by Pfizer Inc. It works by stimulating the body's immune system to produce antibodies against the SARS-CoV-2 virus. The vaccine is indicated for individuals 12 years of age and older, 5 years of age and older, and 6 months through 4 years of age. It has been clinically differentiated through its ability to provide protection against COVID-19 in various age groups. The vaccine's commercial significance is evident in its high revenue of $21.2B. Pfizer Inc. has not disclosed any pipeline developments for this vaccine.","brandName":"BNT162b2 BA.4/5 bivalent","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 virus","novelty":"first-in-class","modality":"mRNA","drugClass":"mRNA vaccine","explanation":"","oneSentence":"","technicalDetail":"The vaccine uses a lipid nanoparticle to deliver the mRNA to the cells, where it is translated into the SARS-CoV-2 protein. The immune system recognizes the protein as foreign and mounts a response, producing antibodies to fight the virus. The vaccine has been shown to be safe and effective in clinical trials."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bnt162b2-ba-4-5-bivalent","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b2-ba-4-5-bivalent","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:38:59.979917+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"BNT162b2 XBB.1.5","company":"Pfizer","advantage":"BNT162b2 XBB.1.5-adapted vaccines were neutralized all JN.1 sublineages with similar potency, indicating a broadly robust and cross-protective immune response."},{"name":"BNT162b2 JN.1","company":"Pfizer","advantage":"BNT162b2 JN.1- and KP.2-adapted vaccines were neutralized all JN.1 sublineages with similar potency, indicating a broadly robust and cross-protective immune response."},{"name":"BNT162b2 KP.2","company":"Pfizer","advantage":"BNT162b2 JN.1- and KP.2-adapted vaccines were neutralized all JN.1 sublineages with similar potency, indicating a broadly robust and cross-protective immune response."},{"name":"BNT162b2 bivalent (WT + BA.4/5)","company":"Pfizer","advantage":"The highest neutralization titers were observed against the BA.4/5 strain for all three vaccine groups."}],"genericName":"bnt162b2-ba-4-5-bivalent","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT05289037","phase":"PHASE2","title":"COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-30","conditions":"COVID-19","enrollment":1270},{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-07-26","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1453},{"nctId":"NCT05543616","phase":"PHASE2, PHASE3","title":"A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-09-23","conditions":"SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19","enrollment":4292},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT06743334","phase":"","title":"Secondary Databased Post-marketing Surveillance Study of BNT162b2","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-23","conditions":"COVID-19, SARS-CoV-2","enrollment":1},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05630352","phase":"PHASE1","title":"A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children","status":"WITHDRAWN","sponsor":"BioNTech SE","startDate":"2025-01-06","conditions":"COVID-19","enrollment":0},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT05749926","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-16","conditions":"Vaccine Reaction, COVID-19","enrollment":248}],"_emaApprovals":[{"date":"","name":"BNT162b2 BA.4/5 bivalent","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5791340"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:38:59.979917+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}